Nicotinamide Mononucleotide

Identification

Generic Name

Nicotinamide Mononucleotide

DrugBank Accession Number

DB03227

Background

3-Carbamoyl-1-beta-D-ribofuranosyl pyridinium hydroxide-5'phosphate, inner salt. A nucleotide in which the nitrogenous base, nicotinamide, is in beta-N-glycosidic linkage with the C-1 position of D-ribose. Synonyms: Nicotinamide Ribonucleotide; NMN. [PubChem]

Type

Small Molecule

Groups

Experimental

Structure

3D

Download

MOLSDF3D-SDFPDBSMILESInChI

Similar Structures

Structure for Nicotinamide Mononucleotide (DB03227)

×

Close

Weight

Average: 335.2271
Monoisotopic: 335.06442701

Chemical Formula

C₁₁H₁₆N₂O₈P

Synonyms

Not Available

Pharmacology

Indication

Not Available

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

See how

Build, train, & validate predictive machine-learning models with structured datasets.

See how

Contraindications & Blackbox Warnings

Prevent Adverse Drug Events Today

Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events with our Clinical API

Learn more

Pharmacodynamics

Not Available

Mechanism of action

Target	Actions	Organism
UADP-ribosyl cyclase 2	Not Available	Humans
UNicotinamide mononucleotide adenylyltransferase 1	Not Available	Humans
UNicotinamide mononucleotide adenylyltransferase 3	Not Available	Humans
UDNA ligase	Not Available	Enterococcus faecalis (strain ATCC 700802 / V583)

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!

See the data

Improve decision support & research outcomes with our structured adverse effects data.

See a data sample

Toxicity

Not Available

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

Not Available

Food Interactions

Not Available

Products

Drug product information from 10+ global regions

Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.

Access now

Access drug product information from over 10 global regions.

Access now

Over the Counter Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
Alpha9	Powder	45 mg/100mg	Topical	Golden Life Health Products Limited	2020-12-23	Not applicable
Elitehealth	Capsule	500 mg/1	Oral	MOHAMMEDJALI Co., Ltd	2023-03-20	Not applicable
Probase Nutrition	Capsule	500 mg/500mg	Buccal	Malaga Imports LLC	2023-04-19	Not applicable
Probase Nutrition	Powder	500 mg/500mg	Oral	Malaga Imports LLC	2023-02-16	Not applicable
Reus Nr	Capsule	600 mg/1	Oral	REUS POLSKA SP Z O O	2023-07-20	Not applicable
Reus Nr	Capsule	600 mg/1	Oral	REUS POLSKA SP Z O O	2023-07-20	Not applicable

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End	Region	Image
Ascuoli	Nicotinamide Mononucleotide (500 mg/1) + Resveratrol (400 mg/1) + White pepper (50 mg/1)	Lozenge	Oral	HEALGROW INC	2023-03-20	Not applicable
Ascuoli	Nicotinamide Mononucleotide (500 mg/1) + Resveratrol (600 mg/1) + White pepper (50 mg/1)	Capsule	Oral	HEALGROW INC	2023-03-20	Not applicable
Herodianow	Nicotinamide Mononucleotide (500 mg/1) + Resveratrol (400 mg/1) + White pepper (50 mg/1)	Lozenge	Oral	HEALGROW INC	2023-09-30	Not applicable
Lovita NMN 12000	Nicotinamide Mononucleotide (200 mg/447mg) + Resveratrol (85 mg/447mg)	Capsule, coated	Oral	ACCOLADE PHARMA USA	2023-06-01	Not applicable
Lovita NMN 18000	Nicotinamide Mononucleotide (300 mg/716.5mg) + Resveratrol (125 mg/716.5mg)	Capsule, coated	Oral	ACCOLADE PHARMA USA	2023-06-01	Not applicable
Lovita NMN 38000	Nicotinamide Mononucleotide (635 mg/900mg) + Resveratrol (100 mg/900mg)	Capsule, coated	Oral	ACCOLADE PHARMA USA	2023-06-01	Not applicable
Nmn	Nicotinamide Mononucleotide (45.8 mg/1001) + Resveratrol (45.8 mg/1001)	Capsule	Oral	IDun Bio-Technology Limited	2021-06-22	Not applicable
Nmn	Nicotinamide Mononucleotide (45.8 mg/1001) + Resveratrol (45.8 mg/1001)	Tablet	Oral	IDun Bio-Technology Limited	2021-06-22	2021-06-28
Nmn	Nicotinamide Mononucleotide (45.8 mg/1001) + Resveratrol (45.8 mg/1001)	Capsule	Oral	IDun Bio-Technology Limited	2021-09-09	Not applicable
Nmn.5s	Nicotinamide Mononucleotide (354 mg/1) + Resveratrol (60 mg/1)	Tablet	Oral	Chengdu Heqi Cosmetics Co., Ltd	2021-03-05	Not applicable

Unapproved/Other Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End	Region	Image
Alpha9	Nicotinamide Mononucleotide (45 mg/100mg)	Powder	Topical	Golden Life Health Products Limited	2020-12-23	Not applicable
Ascuoli	Nicotinamide Mononucleotide (500 mg/1) + Resveratrol (400 mg/1) + White pepper (50 mg/1)	Lozenge	Oral	HEALGROW INC	2023-03-20	Not applicable
Ascuoli	Nicotinamide Mononucleotide (500 mg/1) + Resveratrol (600 mg/1) + White pepper (50 mg/1)	Capsule	Oral	HEALGROW INC	2023-03-20	Not applicable
Elitehealth	Nicotinamide Mononucleotide (500 mg/1)	Capsule	Oral	MOHAMMEDJALI Co., Ltd	2023-03-20	Not applicable
Herodianow	Nicotinamide Mononucleotide (500 mg/1) + Resveratrol (400 mg/1) + White pepper (50 mg/1)	Lozenge	Oral	HEALGROW INC	2023-09-30	Not applicable
Nmn	Nicotinamide Mononucleotide (45.8 mg/1001) + Resveratrol (45.8 mg/1001)	Tablet	Oral	IDun Bio-Technology Limited	2021-06-22	2021-06-28
Nmn	Nicotinamide Mononucleotide (45.8 mg/1001) + Resveratrol (45.8 mg/1001)	Capsule	Oral	IDun Bio-Technology Limited	2021-09-09	Not applicable
Nmn	Nicotinamide Mononucleotide (45.8 mg/1001) + Resveratrol (45.8 mg/1001)	Capsule	Oral	IDun Bio-Technology Limited	2021-06-22	Not applicable
Nmn.5s	Nicotinamide Mononucleotide (354 mg/1) + Resveratrol (60 mg/1)	Tablet	Oral	Chengdu Heqi Cosmetics Co., Ltd	2021-03-05	Not applicable
Nmnpqq	Nicotinamide Mononucleotide (45 mg/100mg) + Pyrroloquinoline Quinone (10 mg/100mg)	Powder	Topical	Golden Life Health Products Limited	2020-12-23	Not applicable

Categories

Drug Categories

• Nucleic Acids, Nucleotides, and Nucleosides
• Nucleotides
• Ribonucleotides

Chemical TaxonomyProvided by Classyfire

Description

This compound belongs to the class of organic compounds known as nicotinamide nucleotides. These are pyridine nucleotides, in which the pyridine base is nicotinamide or a derivative thereof.

Kingdom

Organic compounds

Super Class

Nucleosides, nucleotides, and analogues

Class

Pyridine nucleotides

Sub Class

Nicotinamide nucleotides

Direct Parent

Nicotinamide nucleotides

Alternative Parents

Pentose phosphates / Glycosylamines / Monosaccharide phosphates / Nicotinamides / Monoalkyl phosphates / Pyridinium derivatives / Vinylogous amides / Tetrahydrofurans / Heteroaromatic compounds / Secondary alcohols / Primary carboxylic acid amides / 1,2-diols / Oxacyclic compounds / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives / Organic oxides / Organonitrogen compounds / Organic cations

show 9 more

Substituents

1,2-diol / Alcohol / Alkyl phosphate / Aromatic heteromonocyclic compound / Azacycle / Carboxamide group / Carboxylic acid derivative / Glycosyl compound / Heteroaromatic compound / Hydrocarbon derivative / Monoalkyl phosphate / Monosaccharide / Monosaccharide phosphate / N-glycosyl compound / Nicotinamide / Nicotinamide-nucleotide / Organic cation / Organic nitrogen compound / Organic oxide / Organic oxygen compound / Organic phosphoric acid derivative / Organoheterocyclic compound / Organonitrogen compound / Organooxygen compound / Organopnictogen compound / Oxacycle / Pentose monosaccharide / Pentose phosphate / Pentose-5-phosphate / Phosphoric acid ester / Primary carboxylic acid amide / Pyridine / Pyridine carboxylic acid or derivatives / Pyridinium / Secondary alcohol / Tetrahydrofuran / Vinylogous amide

show 27 more

Molecular Framework

Aromatic heteromonocyclic compounds

External Descriptors

Not Available

Affected organisms

Not Available

Chemical Identifiers

UNII

2KG6QX4W0V

CAS number

Not Available

InChI Key

DAYLJWODMCOQEW-WYOJIJJFSA-O

InChI

InChI=1S/C11H15N2O8P/c12-10(16)6-2-1-3-13(4-6)11-9(15)8(14)7(21-11)5-20-22(17,18)19/h1-4,7-9,11,14-15H,5H2,(H3-,12,16,17,18,19)/p+1/t7-,8-,9+,11+/m0/s1

IUPAC Name

3-carbamoyl-1-[(2R,3R,4R,5S)-3,4-dihydroxy-5-[(phosphonooxy)methyl]oxolan-2-yl]-1lambda5-pyridin-1-ylium

SMILES

NC(=O)C1=CC=C[N+](=C1)[C@@H]1O[C@@H](COP(O)(O)=O)[C@H](O)[C@H]1O

References

General References

Not Available

External Links

PubChem Compound

6093202

PubChem Substance

46506664

ChemSpider

26329944

RxNav

2262276

ChEBI

50383

ZINC

ZINC000053684234

PDBe Ligand

NMN

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
0	Not Yet Recruiting	Treatment	Enhance Immune Function	1
Not Available	Completed	Other	Aging / Coronavirus Disease 2019 (COVID‑19)	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage Forms

Form	Route	Strength
Powder	Topical	45 mg/100mg
Lozenge	Oral
Capsule	Oral	500 mg/1
Capsule, coated	Oral
Capsule	Oral
Tablet	Oral
Powder	Topical
Capsule	Buccal	500 mg/500mg
Powder	Oral	500 mg/500mg
Capsule	Oral	600 mg/1

Prices

Not Available

Patents

Not Available

Properties

State

Solid

Experimental Properties

Not Available

Predicted Properties

Property	Value	Source
Water Solubility	1.8 mg/mL	ALOGPS
logP	-1.5	ALOGPS
logP	-6.2	Chemaxon
logS	-2.3	ALOGPS
pKa (Strongest Acidic)	1.21	Chemaxon
pKa (Strongest Basic)	-1.6	Chemaxon
Physiological Charge	-1	Chemaxon
Hydrogen Acceptor Count	7	Chemaxon
Hydrogen Donor Count	5	Chemaxon
Polar Surface Area	163.42 Å2	Chemaxon
Rotatable Bond Count	5	Chemaxon
Refractivity	71.71 m3·mol-1	Chemaxon
Polarizability	29.2 Å3	Chemaxon
Number of Rings	2	Chemaxon
Bioavailability	1	Chemaxon
Rule of Five	Yes	Chemaxon
Ghose Filter	No	Chemaxon
Veber's Rule	No	Chemaxon
MDDR-like Rule	No	Chemaxon

Predicted ADMET Features

Property	Value	Probability
Human Intestinal Absorption	-	0.9823
Blood Brain Barrier	+	0.8201
Caco-2 permeable	-	0.7581
P-glycoprotein substrate	Non-substrate	0.8055
P-glycoprotein inhibitor I	Non-inhibitor	0.9235
P-glycoprotein inhibitor II	Non-inhibitor	0.9557
Renal organic cation transporter	Non-inhibitor	0.9492
CYP450 2C9 substrate	Non-substrate	0.8213
CYP450 2D6 substrate	Non-substrate	0.8413
CYP450 3A4 substrate	Non-substrate	0.5593
CYP450 1A2 substrate	Non-inhibitor	0.9013
CYP450 2C9 inhibitor	Non-inhibitor	0.9087
CYP450 2D6 inhibitor	Non-inhibitor	0.912
CYP450 2C19 inhibitor	Non-inhibitor	0.8846
CYP450 3A4 inhibitor	Non-inhibitor	0.9644
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.9795
Ames test	Non AMES toxic	0.8159
Carcinogenicity	Non-carcinogens	0.9131
Biodegradation	Not ready biodegradable	0.6569
Rat acute toxicity	2.3780 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9903
hERG inhibition (predictor II)	Non-inhibitor	0.8268

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	Not Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available

Targets

Build, predict & validate machine-learning models

Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.

Learn more

Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.

Learn more

Details1. ADP-ribosyl cyclase 2

Kind

Protein

Organism

Humans

Pharmacological action

Unknown

General Function

Transferase activity

Specific Function

Synthesizes the second messagers cyclic ADP-ribose and nicotinate-adenine dinucleotide phosphate, the former a second messenger that elicits calcium release from intracellular stores. May be involv...

Gene Name

BST1

Uniprot ID

Q10588

Uniprot Name

ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 2

Molecular Weight

35723.545 Da

References

1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]

Details2. Nicotinamide mononucleotide adenylyltransferase 1

Kind

Protein

Organism

Humans

Pharmacological action

Unknown

General Function

Nicotinate-nucleotide adenylyltransferase activity

Specific Function

Catalyzes the formation of NAD(+) from nicotinamide mononucleotide (NMN) and ATP. Can also use the deamidated form; nicotinic acid mononucleotide (NaMN) as substrate with the same efficiency. Can u...

Gene Name

NMNAT1

Uniprot ID

Q9HAN9

Uniprot Name

Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 1

Molecular Weight

31932.22 Da

References

1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]

Details3. Nicotinamide mononucleotide adenylyltransferase 3

Kind

Protein

Organism

Humans

Pharmacological action

Unknown

General Function

Nicotinate-nucleotide adenylyltransferase activity

Specific Function

Catalyzes the formation of NAD(+) from nicotinamide mononucleotide (NMN) and ATP. Can also use the deamidated form; nicotinic acid mononucleotide (NaMN) as substrate with the same efficiency. Can u...

Gene Name

NMNAT3

Uniprot ID

Q96T66

Uniprot Name

Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 3

Molecular Weight

28321.525 Da

References

1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]

Details4. DNA ligase

Kind

Protein

Organism

Enterococcus faecalis (strain ATCC 700802 / V583)

Pharmacological action

Unknown

General Function

Metal ion binding

Specific Function

DNA ligase that catalyzes the formation of phosphodiester linkages between 5'-phosphoryl and 3'-hydroxyl groups in double-stranded DNA using NAD as a coenzyme and as the energy source for the react...

Gene Name

ligA

Uniprot ID

Q837V6

Uniprot Name

DNA ligase

Molecular Weight

75583.155 Da

×

Identify potential medication risks

Easily compare up to 40 drugs with our drug interaction checker.

Get severity rating, description, and management advice.

Learn more

Drug created at June 13, 2005 13:24 / Updated at June 12, 2020 16:52